Specialty Chemicals company Rossari Biotech announced Q3FY26 results Revenue from operations grew 13% to Rs 581.7 crore as compared to Rs 512.7 crore. EBITDA improved by 6% to Rs 68.9 crore from Rs 64.8 crore. EBITDA margin at 11.8% as against 12.6%. PAT increased by 3% to Rs 32.8 crore from Rs 31.7 crore. EPS (Diluted) stood at Rs 5.9 as against Rs 5.7. Edward Menezes, Promoter & Executive Chairman, & Sunil Chari, Promoter & Managing Director, said: “We delivered healthy YoY growth in Q3 FY26 despite a softer domestic demand environment during the quarter. Consolidated revenues grew by 13% YoY, supported by a balanced contribution across business segments and continued traction in our international operations. HPPC recorded a YoY growth of 11% during the quarter, reflecting stable demand amid a softer domestic environment. TSC delivered a growth of 18% YoY, while AHN grew by 39% YoY during the quarter, together providing support to overall growth. The diversified performance across segments helped offset moderation in select end-markets. Exports continued to support overall performance, driven by focused efforts to deepen relationships in key geographies and expand our customer base. Profitability was impacted by ongoing investments in capacity expansion, product development and market-seeding initiatives. These investments are intended to strengthen our long-term competitive positioning, and we remain confident that operating leverage, scale benefits and an improving product mix will support margin improvement over time. Our phased capacity expansion program across verticals continues to progress well, enhancing our manufacturing capabilities. Additionally, we are pleased to announce that the Board has granted in-principle approval to set up greenfield specialty chemicals manufacturing facilities in the Kingdom of Saudi Arabia (KSA).These expansions will support the strategic growth of the Company by improving supply capabilities, accelerating speed-to-market and strengthening the Company’s position as a major player in manufacturing of specialty chemicals. The Project progress will be subject to customary evaluations and necessary regulatory / statutory approvals and is intended to be funded by way of equity, debt, internal accruals, or a combination of these financing means. Looking ahead, we remain focused on disciplined execution, customer-led innovation and sustainable value creation. Supported by strong R&D; capabilities and expanding capacities, we are well-positioned to navigate near-term volatility and deliver consistent, profitable growth for all our stakeholders.” Result PDF